Keyphrases
Chronic Inflammatory Diseases
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
TL1A
100%
Inflammatory Bowel Disease
60%
Tumor Necrosis Factor-α
40%
Anti-tumor Necrosis Factor (anti-TNF)
40%
Family Members
40%
Rheumatoid Arthritis
40%
Psoriasis
20%
Immunobiology
20%
Animal Disease Models
20%
Chronic Inflammation
20%
Serum Concentration
20%
Promising Strategies
20%
Infliximab
20%
Etanercept
20%
Preclinical Intervention Study
20%
Polymorphism
20%
Human Disease
20%
Adalimumab
20%
Immune Targets
20%
Medicine and Dentistry
Inflammatory Disorder
100%
TNF Inhibitor
100%
Tumor Necrosis Factor
100%
Inflammatory Bowel Disease
50%
Inflammatory Arthritis
33%
Rheumatoid Arthritis
33%
Psoriasis
16%
Biological Product
16%
Adalimumab
16%
Immunity
16%
Targeted Therapy
16%
Chronic Inflammation
16%
Clinical Intervention
16%
Immunology
16%
Infliximab
16%
Intervention Study
16%
Etanercept
16%
Immunology and Microbiology
Inflammatory Disorder
100%
TNF Inhibitor
100%
Tumor Necrosis Factor Alpha
80%
Inflammatory Bowel Disease
60%
Inflammatory Arthritis
40%
Tumor Necrosis Factor
40%
Infliximab
20%
Adalimumab
20%
Etanercept
20%
Immunology
20%
Immunity
20%
Biological Product
20%
Blood Level
20%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Tumor Necrosis Factor Inhibitor
100%
Inflammatory Bowel Disease
50%
Inflammatory Arthritis
33%
Rheumatoid Arthritis
33%
Etanercept
16%
Chronic Inflammation
16%
Biological Product
16%
Psoriasis
16%
Intervention Study
16%
Inflammatory Disease
16%
Adalimumab
16%
Infliximab
16%